Piper Sandler raised the price target for the NeoGenomics Inc. (NASDAQ:NEO) stock to ‘an Overweight’. The rating was released on June 03, 2023, according to finviz. We previously noted in another research note published on March 29, 2023 by Stephens that downgraded the stock from an Overweight to an Equal-weight with a price target of $16 for NEO stock. The research report from BofA Securities has downgraded the stock from Buy to Neutral, with a price target set at $18. The stock was resumed by Stephens, who disclosed in a research note on January 18, 2023, to Overweight and set the price objective to $40.
More Stories
Head to Head Analysis: Apollo Investment (NASDAQ:AINV) and Tri-Continental (NYSE:TY)
Tri-Continental (NYSE:TY – Get Rating) and Apollo Investment (NASDAQ:AINV – Get Rating) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses…
Veru Inc. (NASDAQ:VERU) stock Posted Gross Margin of 81.40 percent in Last Year: Is Justifiable?
Jefferies raised the price target for the Veru Inc. (NASDAQ:VERU) stock to ‘a Buy’. The rating was released on April 13, 2021, according t
The Technical Story of Rigel Pharmaceuticals Inc. (RIGL) Stock
Citigroup raised the price target for the Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock from ‘a Buy’ to ‘a Neutral’. The ra
Nasdaq Plummets To Lowest Level In Over A Year In Sell-Off On Wall Street
(RTTNews) – After recovering from an early sell-off in the previous session, stocks showed a substantial move back to the downside during trading …
Swissquote : First half of 2023 Report
Ad hoc announcement pursuant to Art. 53 LR Media information … | June 10, 2023
Would Bed Bath & Beyond Inc. (BBBY) Stock like to attract the attention of traders?
B. Riley Securities lowered the price target for the Bed Bath & Beyond Inc. (NASDAQ:BBBY) stock from ‘a Buy’ to ‘a Neutral